Elute
Elute develops polymer-based drug delivery devices for treating surgical bone infections, enhancing patient outcomes.
Founded
2011Elute develops polymer-based drug delivery devices for treating surgical bone infections, enhancing patient outcomes.
Elute, founded with a mission to revolutionize the treatment of surgical bone infections, focuses on developing polymer-based drug delivery devices. Their flagship product, ElutiBone, is designed to deliver high concentrations of tobramycin directly to infection sites, significantly improving patient outcomes without hindering bone growth. The company targets the orthopedic and surgical markets, aiming to transform the management of peri-prosthetic bone infections through innovative, controlled drug delivery solutions.
Notably, Elute's scientific co-founder, Dr. David Grainger, a University Distinguished Professor at the University of Utah, was inducted into the National Academy of Inventors. This recognition underscores the company's strong scientific foundation. Elute has achieved significant milestones as a clinical-stage company, positioning itself as a leader in patented drug-eluting devices. Their pioneering clinical studies focus on restoring bone loss and reducing recurrent infections, marking a substantial impact on patient care and advancing medical technology in orthopedics.
Companies similar to Elute include Elutia, Reselute, Edulis Therapeutics and Ariste Medical.
Elute was founded in 2011.
Elute's headquarters is located in Salt Lake City, UT, US.
Elute's most recent funding round was for $1.6M (USD) in March 2016.
As of Mar 31, 2016, Elute has disclosed funding of $1.6M (USD). Undisclosed round amounts are excluded.
Elute has 5 employees as of Feb 5, 2024.
